Literature DB >> 20200515

Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases.

M Arrese1, S J Karpen.   

Abstract

Members of the nuclear receptor (NR) superfamily of ligand-activated transcription factors are players of substantial relevance in the regulation of hepatic gene expression. NRs direct normal physiology and metabolism, adaptations to liver disease, and responses to inflammation and toxins.They also contribute to the regenerative response. In this review, we summarize currently available experimental and clinical data, focusing on the role of NRs in cholestasis and nonalcoholic fatty liver disease (NAFLD). We also highlight the potential of NRs as targets for safe and effective therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20200515      PMCID: PMC4120751          DOI: 10.1038/clpt.2010.2

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  37 in total

Review 1.  Principles for modulation of the nuclear receptor superfamily.

Authors:  Hinrich Gronemeyer; Jan-Ake Gustafsson; Vincent Laudet
Journal:  Nat Rev Drug Discov       Date:  2004-11       Impact factor: 84.694

2.  Nuclear factor-kappaB inhibition and non-alcoholic steatohepatitis: inflammation as a target for therapy.

Authors:  Fabio Marra
Journal:  Gut       Date:  2008-05       Impact factor: 23.059

3.  Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic inflammation.

Authors:  Martin Wagner; Gernot Zollner; Michael Trauner
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

Review 4.  Physiology and pathophysiology of liver inflammation, damage and repair.

Authors:  G Ramadori; F Moriconi; I Malik; J Dudas
Journal:  J Physiol Pharmacol       Date:  2008-08       Impact factor: 3.011

Review 5.  Review: The role of insulin resistance in nonalcoholic fatty liver disease.

Authors:  Kristina M Utzschneider; Steven E Kahn
Journal:  J Clin Endocrinol Metab       Date:  2006-09-12       Impact factor: 5.958

6.  Enhanced expression of basolateral multidrug resistance protein isoforms Mrp3 and Mrp5 in rat liver by LPS.

Authors:  Markus G Donner; Ulrich Warskulat; Nirmalendu Saha; Dieter Häussinger
Journal:  Biol Chem       Date:  2004 Mar-Apr       Impact factor: 3.915

Review 7.  Nuclear receptors as therapeutic targets in cholestatic liver diseases.

Authors:  Gernot Zollner; Michael Trauner
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

8.  Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response.

Authors:  Yan-Dong Wang; Wei-Dong Chen; Meihua Wang; Donna Yu; Barry M Forman; Wendong Huang
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

Review 9.  Nuclear receptors: mediators and modifiers of inflammation-induced cholestasis.

Authors:  Jaap Mulder; Saul J Karpen; Uwe J F Tietge; Folkert Kuipers
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

10.  Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: A novel mechanism for reduced hepatic gene expression in inflammation.

Authors:  Romi Ghose; Tracy L Zimmerman; Sundararajah Thevananther; Saul J Karpen
Journal:  Nucl Recept       Date:  2004-08-16
View more
  11 in total

Review 1.  Farnesoid x receptor agonists: what they are and how they might be used in treating liver disease.

Authors:  Brent A Neuschwander-Tetri
Journal:  Curr Gastroenterol Rep       Date:  2012-02

Review 2.  Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet?

Authors:  Swetha Rudraiah; Xi Zhang; Li Wang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016       Impact factor: 13.820

3.  RNA-Seq reveals common and unique PXR- and CAR-target gene signatures in the mouse liver transcriptome.

Authors:  Julia Yue Cui; Curtis D Klaassen
Journal:  Biochim Biophys Acta       Date:  2016-04-23

4.  Exposure to 2,4-dichlorophenoxyacetic acid induced PPARβ-dependent disruption of glucose metabolism in HepG2 cells.

Authors:  Haidong Sun; Wentao Shao; Hui Liu; Zhaoyan Jiang
Journal:  Environ Sci Pollut Res Int       Date:  2018-04-09       Impact factor: 4.223

5.  In-depth proteomic characterization of endogenous nuclear receptors in mouse liver.

Authors:  Qiongming Liu; Chen Ding; Wanlin Liu; Lei Song; Mingwei Liu; Liang Qi; Tianyi Fu; Anna Malovannaya; Yi Wang; Jun Qin; Bei Zhen
Journal:  Mol Cell Proteomics       Date:  2012-11-29       Impact factor: 5.911

6.  Non-alcoholic Fatty liver disease: the bile Acid-activated farnesoid x receptor as an emerging treatment target.

Authors:  Michael Fuchs
Journal:  J Lipids       Date:  2011-12-07

7.  Nuclear receptors in nonalcoholic Fatty liver disease.

Authors:  Jorge A López-Velázquez; Luis D Carrillo-Córdova; Norberto C Chávez-Tapia; Misael Uribe; Nahum Méndez-Sánchez
Journal:  J Lipids       Date:  2011-12-08

8.  A network biology workflow to study transcriptomics data of the diabetic liver.

Authors:  Martina Kutmon; Chris T Evelo; Susan L Coort
Journal:  BMC Genomics       Date:  2014-11-15       Impact factor: 3.969

Review 9.  Biological functions of thyroid hormone in placenta.

Authors:  Cheng-Yi Chen; Chie-Pein Chen; Kwang-Huei Lin
Journal:  Int J Mol Sci       Date:  2015-02-16       Impact factor: 5.923

10.  Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity via Activation of Farnesyl X Receptor.

Authors:  Ming Gu; Ping Zhao; Jinwen Huang; Yuanyuan Zhao; Yahui Wang; Yin Li; Yifei Li; Shengjie Fan; Yue-Ming Ma; Qingchun Tong; Li Yang; Guang Ji; Cheng Huang
Journal:  Front Pharmacol       Date:  2016-09-28       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.